Your browser doesn't support javascript.
loading
Oxycodone: a pharmacological and clinical review
Ordóñez Gallego, A; González Barón, M; Espinosa Arranz, E.
Afiliação
  • Ordóñez Gallego, A; Universidad Autónoma de Madrid. La Paz University Hospital Madrid. Madrid. Spain
  • González Barón, M; Universidad Autónoma de Madrid. La Paz University Hospital Madrid. Madrid. Spain
  • Espinosa Arranz, E; Universidad Autónoma de Madrid. La Paz University Hospital Madrid. Madrid. Spain
Clin. transl. oncol. (Print) ; 9(5): 298-307, mayo 2007. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-123310
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
Oxycodone is a semi-synthetic opioid with an agonist activity on mu, kappa and delta receptors. Equivalence with regard to morphine is 12. Its effect commences one hour after administration and lasts for 12 h in the controlled-release formulation. Plasma halflife is 3-5 h (half that of morphine) and stable plasma levels are reached within 24 h (2-7 days for morphine). Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%. Most of the drug is metabolised in the liver, while the rest is excreted by the kidney along with its metabolites. The two main metabolites are oxymorphone--which is also a very potent analgesic--and noroxycodone, a weak analgesic. Oxycodone metabolism is more predictable than that of morphine, and therefore titration is easier. Oxycodone has the same mechanism of action as other opioids binding to a receptor, inhibition of adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability. These mechanisms also play a part in the onset of dependence and tolerance. The clinical efficacy of oxycodone is similar to that of morphine, with a ratio of 1/1.5-2 for the treatment of cancer pain. Long-term administration may be associated with less toxicity in comparison with morphine. In the future, both opioids could be used simultaneously at low doses to reduce toxicity. It does not appear that there are any differences between immediate and slow-release oxycodone, except their half-life is 3-4 h, and 12 h, respectively. In Spain, controlled-release oxycodone (OxyContin) is marketed as 10-, 20-, 40- or 80-mg tablets for b.i.d. administration. Tablets must be taken whole and must not be broken, chewed or crushed. There is no food interference. The initial dose is 10 mg b.i.d. for new treatments and no dose reduction is needed in the elderly or in cases of moderate hepatic or renal failure. Immediate-release oxycodone (OxyNorm) is also available in capsules and oral solution. Side effects are those common to opioids mainly nausea, constipation and drowsiness. Vomiting, pruritus and dizziness are less common. The intensity of these side effects tends to decrease over the course of time. Oxycodone causes somewhat less nausea, hallucinations and pruritus than morphine (AU)
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Oxicodona / Dor / Medição da Dor / Clínicas de Dor / Manejo da Dor / Analgésicos Opioides Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2007 Tipo de documento: Artigo Instituição/País de afiliação: Universidad Autónoma de Madrid/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Oxicodona / Dor / Medição da Dor / Clínicas de Dor / Manejo da Dor / Analgésicos Opioides Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2007 Tipo de documento: Artigo Instituição/País de afiliação: Universidad Autónoma de Madrid/Spain
...